Alpharadin (radium-223)

More From the 2013 ASCO GU Conference – An Updated Analysis of the Phase III Randomized Trial (ALSYMPCA) of Radium-223 dichloride (Ra-223)

Ra-223 is an investigational alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range alpha-particles. The recently completed phase 3, double-blind, randomized, multinational ALSYMPCA study showed that Ra-223 significantly improved over all survival (OS) in CRPC men with bone mets by a median increase of 3.6 months compared with placebo (median OS: 14.9 vs 11.3 mo; P [...]

By Malecare|2017-10-19T10:50:08-04:00February 28th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized|0 Comments

Great News for the Advanced Prostate Cancer Community – The FDA Grants a Priority Review for Radium-223 Dichloride (Alpharadin)

Some more good news for the advanced prostate cancer community was announced today. Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has granted priority review to their New Drug Application (NDA) filed in December 2012 for the investigational oncology compound radium-223 dichloride (radium-223). The application is under review for the treatment of [...]

By Malecare|2020-02-04T08:22:15-05:00February 13th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), Clinical Trials, Clinical Trials, FDA, General Information, Uncategorized|0 Comments

Two New Sites Available for Early Access to Alpharadin

There are now two new, additional sites added to the Early Access Trial of the investigational treatment known as Radium-233 or Alpharadin for men with castrate resistant prostate cancer with multiple bone metastases. This post contains the most up to date and accurate information, the clinical trials.gov site is NOT currently accurate. Additionally, there are [...]

By Malecare|2017-10-19T10:50:24-04:00December 31st, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Metastases, Uncategorized|0 Comments

Dr. Sartor Announces Bayer has Requested FDA Approval of Alpharedin & He Will Join Malecare to Make a Pod Cast Upon its Approval

On Thursday evening I had the opportunity to meet Dr. Oliver Sartor from the University of Tulane. At that time he informed me that Bayer had finally submitted the required paperwork to the FDA for formal approval of radium-233 chloride. For those of you who are not familiar with Dr. Sartor, he is both an [...]

By Malecare|2012-12-17T09:18:40-05:00December 17th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Early/Expanded Access Programs, FDA, On The Horizon, Radiotherapy, Uncategorized, Understanding APC|2 Comments

Two New Sites Open for Early/Expanded Access to Radium-233 (Alapharedin) in Fort Meyers, FL. & Philadelphia, PA

The Early/Expanded Access Committee has been continuing to work on getting additional sites open for men with advanced prostate cancer to get access to the yet unapproved drug Radium-233 Chloride (Alapharadin). Due to the hard work of this committee there are now sites in seven different states. In order to qualify for this treatment you [...]

By Malecare|2020-02-04T11:08:09-05:00December 7th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Early/Expanded Access Programs, Uncategorized, Understanding APC|0 Comments